As such, identifying new biomarkers has become an increasing focus in 21st century drug discovery and development, and the inclusion of molecular markers in clinical trial design allows for the retrospective analysis of data and the identification of patient sub-groups that are likely to respond to a given therapy.
As for technology platforms to identify biomarkers that inform drug discovery efforts, the systems and techniques involved are intricate lab processes, from tissue microarrays and gene expression profiling to proteomics and mass spectrometry, as well as machine learning and other bioinformatics-based methods of interpreting data and validating whether biomarkers have diagnostic, predictive or prognostic value.
